{
  "id": 5914426,
  "title": "Pulmovant to present phase 2 mosliciguat study results Tuesday",
  "url": "https://urgent.news/2026/09/06/pulmovant-to-present-phase-2-mosliciguat-study-results-tuesday",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-06T05:04:41.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/pulmovant-to-present-phase-2-mosliciguat-study-results-tuesday-93CH-4890257"
  },
  "original_language": "en",
  "account": "Pulmovant, a clinical-stage biotech firm and Roivant subsidiary, will unveil Phase 2 results of its mosliciguat study on pulmonary hypertension linked to interstitial lung disease. The data will be unveiled at the European Respiratory Society International Congress 2026. Marc Humbert, a leading expert in the field, will deliver the presentation at 12:15 CEST (6:15 a.m. ET) on September 8, 2026. The Phase 2 PHOCUS trial is a global, double-blind study involving 135 adult patients. It aims to evaluate the drug's safety and effectiveness. Pulmovant is also studying mosliciguat in combination with inhaled treprostinil in a Phase 2 PHACTOR trial. Inhaled mosliciguat demonstrated a mean peak reduction of up to 38% in pulmonary vascular resistance in a previous Phase 1b study. Pulmonary hypertension associated with interstitial lung disease impacts approximately 200,000 patients in the U.S. and Europe.",
  "summary": null,
  "key_points": [
    "Pulmovant to present Phase 2 mosliciguat study results on September 8, 2026",
    "Study focuses on pulmonary hypertension linked to interstitial lung disease",
    "Marc Humbert to deliver presentation at European Respiratory Society Congress"
  ],
  "editors_take": "The upcoming presentation of mosliciguat study results marks a crucial step for Pulmovant in advancing its treatment for pulmonary hypertension linked to interstitial lung disease, a condition affecting a significant patient population.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}